Contributed by Kailash Bhatia, MD
Institute of Neurology
2019 Updates Contributed by:
Petra Dosekova, MD
Movement Disorders Unit and Center for Rare Movement Disorders,
Dept. of Neurology
P. J. Safarik University
Stiff Person Syndrome (SPS) is a rare autoimmune movement disorder that affects central nervous system and is clinically characterized by muscle stiffness, spasms and increased startle response (unconscious defensive response) to unexpected stimuli.
SPS belongs to the group of Stiff person syndrome spectrum disorders (SPSD) that share the same clinical features and spectrum of antibodies against neuronal proteins, that participate in normal inhibition of central hyperexcitability which explains its clinical characteristics. The exact pathophysiological mechanism is still not known.
Muscle stiffness usually begins insidously in lower back and legs and can mimic lower back pain, but in time tends to progress to other body parts, mainly to distal limb parts and abdominal muscles. As a result patients present with typical “stiff” or “robotic” gait with exaggerated lumbar hyperlordosis. Stiffness usually resolves in sleep or under anesthesia.
Muscle spasms in SPS are painful and intermittent. They typically occur as a result of unexpected external stimuli, mainly to tactile, acoustic or emotional stimulus and usually last for few seconds or minutes. Extreme spasms can lead to spontaneous fractures and joint subluxations or uncontrolled falls of the person with typical “log-like” falling down.
Patients with SPS also often manifest non-motor features such as anxiety, depression and task specific phobias. The most common is agoraphobia, with fear of falling down if walking unaided. Also, there can be transient symptoms of autonomic dysfunction leading to sympathetic hyperactivity with diaphoresis, hyperpyrexia or sexual dysfunctions.
Besides classical SPS there are focal forms of disease when symptoms are isolated on one body part, e.g. Stiff limb syndrome, or forms associated with additional neurological features (e.g. epilepsy, ataxia, polyneuropathy) and also fulminant and sometimes fatal forms such as Progressive encephalomyelopathy with rigidity and myoclonus (PERM).
Diagnosis of SPS is based on its clinical presentation. Findings of elevated standard antibodies titres against GAD, glycine, DPPX, GABARAP, gephyrin and ampiphysine in cerebrospinal fluid and blood may be helpful but are not crucial for the diagnosis. EMG studies show unspecific continuous motor unit activity potentials (CMAP) in affected muscles. Electrophysiological studies of exteroceptive reflexes with abnormal masseter inhibitory reflex with loss of S2 component, and shortened latency of R2 recovery in Blink reflex are more specific.
Brain and spine MRI are normal and are used only to exclude other possible diagnoses.
SPS is commonly associated with other autoimmune diseases, including vitiligo, diabetes mellitus and thyroiditis. Some forms (mainly associated with anti-ampiphysin antibodies) may be associated with neoplasms.
The therapy of SPSD is based on the triad of symptomatic treatment, immunotherapy, and tumor removal/oncological treatment where appropriate.
Symptomatic treatment is based on drugs with GABA-ergic action. Nevertheless, due to its autoimmune nature, the core treatment is immunotherapy utilizing corticosteroids, intravenous immunoglobulins (IVIG) and/or plasma exchange as first line therapy, escalated to second line immunotherapy utilizing e.g. cyklosporin, cyklofosfamid or mycofenolat mofetil in unresponsive cases. Treatment of the underlying oncological process is crucial in cases with paraneoplastic association.
The prognosis of the disease is variable.
Click here to view videos depicting stiff person syndrome (Members Only)